Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A Phase II Study, published in The Lancet Obstetrics, Gynaecology & Women's Health, highlights the potential of a new molecular imaging agent, ‘99mTc-maraciclatide’, when used alongside a non-invasive scan to diagnose and monitor the development and treatment of Endometriosis.

A black young girl in pain due to Endometriosis

The study, “Detecting Endometriosis Expressed Integrins using Technetium-99m (DETECT)”, is a collaboration between clinical radiopharmaceutical company, Serac Healthcare Ltd and the Nuffield Department of Women’s & Reproductive Health.

About the study

The study evaluated 19 individuals with suspected or confirmed pelvic or thoracic endometriosis. Participants underwent preoperative SPECT-CT imaging, a non-invasive scan, following intravenous administration of 99mTc-maraciclatide.

This imaging agent binds to αvβ3 integrins, which are upregulated during angiogenesis (the formation of new blood vessels), a key feature of inflammatory diseases such as endometriosis. By visualising this process, the scan can detect areas of disease.

The study found that this non-invasive approach performed comparably to laparoscopic surgery in detecting endometriosis. 

Read the full story on the Nuffield Department of Women's & Reproductive Health website.